South Korea's biotechnology industry stands at a crucial turning point. Recently, global financial institution ING Research identified South Korea as Asia's "second innovation engine" following China. This recognition signifies that the biotechnology sector, alongside semiconductors and automobiles, is acknowledged as a key driver of South Korea's future growth on the international stage. In fact, South Korea has established significant global competitiveness in the biosimilar and contract development and manufacturing (CDMO) sectors, attracting attention from the global market. Last year, pharmaceutical and biotechnology exports reached $10.4 billion (16 trillion won), surpassing the $10 billion mark for the first time, while the industry's technology export volume also hit a record high of approximately $13.7 billion (20.7 trillion won).
However, behind these impressive achievements, warning signs are emerging. The growth rate of clinical trials is slowing, and the number of new drug approvals is declining. In a global environment where competition for biopharmaceutical dominance is intensifying, this stagnation could pose a threat to the future of South Korea's biotechnology industry.
The South Korean biotechnology sector has historically grown based on its manufacturing competitiveness. Companies like Celltrion and Samsung Bioepis have pioneered the biosimilar market, while Samsung Biologics has become the world's largest CDMO company. These are certainly commendable accomplishments. However, relying solely on biosimilars and contract manufacturing will make it difficult to maintain a leading position in the global market over the long term. Ultimately, true competitiveness stems from the development of innovative drugs.
The reason major pharmaceutical companies leading the global market, such as Pfizer, Merck, and Johnson & Johnson in the U.S., and Roche and Novartis in Europe, generate substantial profits is due to innovative drugs. A single blockbuster drug can create market value worth tens of trillions of won. This is why South Korea must leap from being a manufacturing powerhouse to becoming a leader in innovative drug development.
The challenge lies in the fact that the pace of innovation in the industry is not matched by regulatory frameworks. Domestic biotechnology companies cite lengthy approval processes, complex reimbursement evaluations, and unpredictable pricing policies as significant obstacles. New drug development is a high-risk industry with a very low success rate. It is not uncommon for companies to invest hundreds of billions of won in research and development only to face failure. In such an environment, adding regulatory uncertainty makes it difficult for companies to take bold risks.
Particularly concerning is China's rapid advancement. With comprehensive national support, China is quickly expanding its capabilities in clinical trials and new drug development. Its share of global clinical trials is also increasing rapidly. Areas where South Korea once held a relative advantage in the biotechnology sector are now being swiftly encroached upon by China. If the current regulatory environment persists, South Korea's competitive edge cannot be taken for granted.
Of course, regulatory innovation does not mean an unconditional easing of regulations. The principles of public health and safety must be upheld. However, it is entirely possible to shorten review periods while maintaining safety, make approval and reimbursement processes more predictable, and establish a reasonable compensation system for innovative technologies.
Fortunately, South Korea possesses world-class medical infrastructure, excellent research personnel, and global-level production capabilities. Additionally, the recent increase in technology exports and the expansion of investments from foreign pharmaceutical companies further demonstrate the potential of South Korea's biotechnology sector. What is now needed is a collaborative effort between the industry to take risks and the government to innovate regulations.
South Korea is already recognized as a "biotechnology production powerhouse." However, the true goal should not stop there. The country must evolve into one where innovative technologies born in laboratories transition to clinical applications and ultimately yield new drugs that change the lives of patients worldwide. The next leap for K-Bio will not be achieved solely through the research and development efforts of companies. Only when regulatory innovations and policy support that align with the changing times accompany these efforts can South Korea rise above being a production powerhouse to become a leader in innovative drug development.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.